Dr. Dennis Hsu, MD

Dr. Hsu practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Dr. Hsu's NPI, 1225474117, was assigned on May 17, 2013. Dr. Hsu holds Pennsylvania license MD475322.

Dr. Hsu's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Dr. Hsu's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Dr. Hsu is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Hsu to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hsu practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hsu's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Hsu's licenses on file in 3 states: Pennsylvania, Michigan and New York.

CMS data shows 56 Medicare services from Dr. Hsu across 2 procedure codes in 2024, for 50 Medicare patients. Medicare paid $5,303 for them.

CMS counts 50 Medicare patients who saw Dr. Hsu in 2024. The largest group is 65 to 74, with 31 patients. 72% of them have cancer, and 72% have high blood pressure. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hsu's median patient age at 68, with 53% women.

In 2024, Dr. Hsu wrote 71 Medicare Part D claims for 17 patients. 76% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $8,346 in total drug cost. In 2023, CMS named 46 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Hsu for performance year 2024, reported as part of a group. Dr. Hsu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hsu as offering telehealth.

Dmand AI links 14 papers to Dr. Hsu, published from 2012 to 2024. 2023 was the busiest year, with 4. The most frequent topics are Colorectal Neoplasms, Cell Line, Tumor and Antineoplastic Agents. Dr. Hsu has published most often in JCO Oncol Pract. Dr. Hsu's most frequent co-authors are Janie Yue Zhang, MD, Sohail Fakhr Tavazoie, MD and Vikram C. Gorantla.

CMS Open Payments shows 5 general payments to Dr. Hsu from 5 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 69% of the total. Amgen Inc. paid the most, $736. It also lists 1 research payment totaling $110 in 2025, naming 1 clinical trial.